当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Salivary Type Hyperamylasemia as a Sign of the Presence of Ovarian Cancer

Alessandro di Federico*, Daria M. Filippini , Daniela Rubino , Anna Mandrioli and Claudio Zamagni

Lifetime risk of developing Ovarian Cancer (OC) in women is 13% (1 in 75). Unfortunately, only a minority of cases (15%) are diagnosed in stage 1, with a 5-year survival rate of 92%. Conversely, at a late stage, when mostly patients are diagnosed, it is only 29% [1]. Serum tumor markers are largely used in gynecological malignancies. Among them, Carbohydrate Antigen 125 (CA 125) certainly is the most used in OC. Despite its lack of specificity, as it can be found elevated in different malignant and nonmalignant conditions, such as the presence of pleural or peritoneal effusion, it has been widely used to help predicting the nature of a pelvic mass as well as during cancer treatment and its follow-up.